期刊文献+

双氯芬酸钠肠溶缓释片的制备及体外释放度的研究

Study on Diclofenac Sodium Enteric-coated Sustained-release Tablets Preparation and in Vitro Release
下载PDF
导出
摘要 以HPMC K15M、HPMC K4M制备双氯芬酸钠亲水凝胶骨架片,采用肠溶欧巴代进行包衣,并研究了肠溶缓释片的体外释放度。缓释片处方为主药∶HPMC K15M∶HPMC K4M∶MCC∶乳糖∶硬脂酸镁=75∶50∶20∶115∶40∶3;包衣材料为12%的肠溶欧巴代水溶液,药片增重3%~4%;体外释放情况为2h:37.2%,6h:70.9%,12h:92.2%,对药物的释放情况进行拟合,符合一级方程。 We use HPMC K15M&HPMC K4M to make preparation of Diclofenac Sodium hydrophlic gel matrix sustained-release tablets, the enteric material is Opadry. And study the in vitro dissolution rate of enteric-coated sustained-release tablets. The formulation of sustained release tablets is Drug: HPMC K15M: HPMC K4M: MCC: lactose: =75: 50: 20: 115: 40: 3. The coating materials is 12% enteric Opadry aqueous solution,tablet weight in- crease of 3% to 4% ;In vitro release of 2h :37.2% ,6h :70. 9%, 12h :92. 2% ,fitting the release of the drug with the first-order equation.
作者 刘思佼 王明旭 LIU Si-jiao WANG Ming-xu(Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China)
机构地区 西安交通大学
出处 《合成材料老化与应用》 2017年第2期76-78,共3页 Synthetic Materials Aging and Application
关键词 双氯酚酸钠 缓释片 肠溶片 体外释放度 diclofenac sodium, enteric-coated, sustained-release, in vitro release
  • 相关文献

参考文献3

二级参考文献44

  • 1[1]Lichtenstein D, Syngal S, Wlfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rherm,1995;38:1:5~18.
  • 2[2]Bjarnason I, Macpherson A, Somasundaram S, et al. Lower bowel toxicity of non-steroidal anti-inflammatory drugs. Lewis A: Non-steroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Uses. New York: NY, Marcel Dekker, 1994;145~157.
  • 3[3]Marie R, Griffin, MD. Epidemiology of non-steroidal antiinflammatory drug-associated gastrointestinal injury. Am J Med.1998;104: 23~28.
  • 4[4]Fujiwara Y, Schmassman A, Arakawa T, et al. Indomethacin interferes with epidermal growth factor binding and proliferative response of KATO Ⅲ cells. Digestion, 1995;56:364~369.
  • 5[5]Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales.Gastroenterology. 1993; 104:1083~ 1091.
  • 6[6]Fries JF, Williams CA, Michel BA et al. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med, 1991 ;91:213 ~222.
  • 7[7]Gutthamm SP, García LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and the risk of hospitalization for upper gastrointestinal bleeding and perforation in saskatche wan: a nested case-control study. Pharmacoepidemiol Drug Safety. 1994;3:S63.
  • 8[8]Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term non-steroidal anti-inflammatorydrug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology, 1992;102 :1899~1905.
  • 9[9]Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet, 1994 ;34 3 :107 5-107 8
  • 10[10]Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. am J Med, 1999;106:13~23.

共引文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部